Research library

Key finding

In men, combined stimulation of the GHRH and ghrelin pathways produced synergistic pulsatile growth-hormone release, with responses influenced by age, sex steroids and visceral fat.

Key finding

A single CJC-1295 dose produced sustained, dose-dependent increases in growth hormone and IGF-1 in healthy adults for several days and was generally well tolerated.

Key finding

Ipamorelin stimulated potent growth-hormone release in animal models while showing markedly less ACTH and cortisol release than comparator secretagogues.

Key finding

In healthy volunteers, ipamorelin produced dose-related growth-hormone responses across the tested dose range.

Key finding

CJC-1295's albumin-binding design extended peptide exposure and maintained activation of the growth-hormone-releasing factor receptor in rats.

Key finding

CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility.

Key finding

Although the molecular mechanisms linking the identified proteins to GH and IGF-1 biological activity remain to be clarified, the results suggest that they represent potential biomarkers of GH and/or IGF-1 action.

Key finding

The authors reported that ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Key finding

Ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility.

Key finding

Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells.

Key finding

Growth hormone secretagogues (GHSs) stimulate growth hormone (GH) secretion, which is lipolytic.

Key finding

Growth hormone (GH) is of importance for normal bone remodelling.

Key finding

Ipamorelin 0.03-mg/kg twice daily for up to 7 days was well tolerated.

Key finding

The administration of growth hormone releasing hormone (GHRH) and its synthetic analogs is prohibited by the World Anti-Doping Agency (WADA).

Key finding

Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List.

Key finding

CJC-1295 is a 30 amino acid peptide-based drug that stimulates the release of growth hormone (GH) from the pituitary gland.

Key finding

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life.

Key finding

Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties.

Key finding

NN703 is a novel orally active GH secretagogue (GHS) derived from ipamorelin.

Key finding

The present study was undertaken to study the growth hormone-releasing properties and growth-promoting effect of a GH secretagogue ipamorelin (IPA) in rats given the synthetic glucocorticoid methylprednisolone (MP).